KRAS Activating Mutation clinical trials at UCSF
1 research study open to eligible people
KRAS activating mutation causes cancer. UCSF is recruiting for a clinical trial for people with G12C Non-Small Cell Lung Cancer. The trial is testing the medications avutometinib and adagrasib together for those who have had previous G12C treatment.
open to eligible people ages 18 years and up
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.
San Francisco, California and other locations
Our lead scientists for KRAS Activating Mutation research studies include Collin Blakely, MD.